依帕司他联合甲钴胺治疗2型糖尿病周围神经病变的有效性及安全性  

Efficacy and safety of epalrestat combined with mecobalamin in the treatment of type 2 diabetic peripheral neuropathy

作　　者：林源[1] 高海燕[1] 郭亚菊[1] 宋书贤[1] 

机构地区：[1]西安医学院第二附属医院,陕西西安710038

出　　处：《临床医学研究与实践》2018年第2期30-31,共2页Clinical Research and Practice

摘　　要：目的探讨依帕司他联合甲钴胺对2型糖尿病周围神经病变的治疗效果及安全性。方法将我院收治的78例2型糖尿病周围神经病变患者随机分成观察组和对照组,各39例。观察组给予依帕司他及甲钴胺口服;对照组给予甲钴胺口服。观察两组患者的临床疗效、神经传导速度及不良反应发生情况。结果治疗后,观察组治疗总有效率为89.74%,高于对照组的56.41%(P<0.05);治疗1、3个月后,两组患者SNCV、MNCV均显著改善,且观察组优于对照组(P<0.05);两组患者均无严重不良反应发生。结论依帕司他联合甲钴胺治疗2型糖尿病周围神经病变疗效显著,安全性高,值得临床推广。Objective To investigate the effect and safety of epalrestat combined with mecobalamin in the treatment oftype 2 diabetic peripheral neuropathy. Methods A total of 78 patients with type 2 diabetic peripheral neuropathy treated inour hospital were selected as the research objects, and randomly divided into observation group and control group, with 39cases in each group. The observation group was given epalrestat and mecobalamin oral treatment; and the control group wasgiven mecobalamin oral treatment. The clinical effects, nerve conduction velocity, adverse reactions of the two groups wereobserved. Results After treatment, the total effective rate of the observation group was 89.74%, which was higher than56.41% of the control group （P约0.05）. At 1, 3 months after treatment, the SNCV and MNCV in both groups improved, andthose in the observation group were better than the control group （P〈0.05）; there were no serious adverse reactions in thetwo groups. Conclusion Epalrestat combined with mecobalamin in the treatment of type 2 diabetic peripheral neuropathyhas significant effect, with high safety, which is worthy of clinical promotion.

关 键 词：依帕司他 甲钴胺 2型糖尿病周围神经病变 

分 类 号：R587.2[医药卫生—内分泌]